Erdong Hua is a Partner at 6 Dimensions Capital based in its Shanghai office and he has over 10 years of dedicated experiences of life sciences and healthcare investment. Mr. Hua was a Partner at Frontline BioVentures before the formation of 6 Dimensions Capital through a merger between Frontline BioVentures and WuXi Healthcare Ventures in May 2017. At 6 Dimensions and Frontline, Mr. Hua led and participated in the investments of Biokangtai (SZ:300601), Guoke Hengtai, Neusoft Medical, Yikon Genomics, AnchorDx, Hua Medicine (HK:2552), WellVac, 111, Inc. (Nasdaq:111) and Grail. Prior to Frontline, Mr. Hua was co-founder and COO of BilanxCode Functional Medicine and before that, he acted as a board observer and headed Business Development at DeltaHealth (China). Mr. Hua joined Fidelity Asia Ventures, Shanghai Representative Office in 2007 as an investment professional, serving both TMT and Healthcare workgroups.

Mr. Hua earned his B.S from Tongji University as a cum laude graduate and gain experience as an investment banker and consultant before his venture capitalist career.